FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews
Routine sharing of data between FDA and CMS will be possible for the first time under a June 23 memorandum of understanding that could serve as a first step toward parallel reviews for marketing approval and Medicare coverage
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
